Stryker Corporation $SYK Shares Purchased by Focus Partners Wealth

Key Points

• Focus Partners Wealth increased its stake in Stryker Corporation by 1.7% during Q1, now holding 130,156 shares valued at about $48,451,000.
• Insider Ronda E. Stryker sold 200,000 shares at an average price of $376.45, reducing her ownership by 5.84% but retaining over 3.2 million shares.
• Analysts have set a consensus price target of $431.42 for Stryker, with most rating the stock as a "Moderate Buy."

Focus Partners Wealth grew its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,156 shares of the medical technology company's stock after acquiring an additional 2,167 shares during the quarter. Focus Partners Wealth's holdings in Stryker were worth $48,451,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of SYK. Capital A Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at about $26,000. Goodman Advisory Group LLC acquired a new position in shares of Stryker during the first quarter valued at about $32,000. City Holding Co. boosted its position in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in Stryker in the first quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SYK shares. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Citigroup reiterated a "buy" rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Needham & Company LLC upped their target price on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wells Fargo & Company upped their target price on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Finally, Truist Financial set a $415.00 target price on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $431.42.

Stryker Trading Down 2.4%

Stryker stock opened at $383.22 on Thursday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock's 50 day simple moving average is $389.22 and its two-hundred day simple moving average is $379.70. The firm has a market cap of $146.51 billion, a PE ratio of 50.76, a P/E/G ratio of 2.86 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the prior year, the firm posted $2.81 EPS. The business's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio (DPR) is 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.